Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Talazoparib + Radiotherapy for Small Cell Lung Cancer
Recruiting1 awardPhase 1
Toronto, Ontario
This trial is testing whether combining talazoparib with low dose consolidative thoracic radiotherapy is safe and what the maximum tolerated dose is. Patients will take talazoparib orally once daily starting on the first day of study intervention until the last day of radiation therapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service